Verona Pharma to trial lung drug ensifentrine for COVID-19Verona Pharma is to develop its lung drug ensifentrine for patients with COVID-19, joining the legions of drug Share XVerona Pharma to trial lung drug ensifentrine for COVID-19https://pharmaphorum.com/news/verona-pharma-to-develop-lung-drug-for-covid-19/
AZ’s COPD triple therapy approved in the USAstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the Share XAZ’s COPD triple therapy approved in the UShttps://pharmaphorum.com/news/azs-copd-triple-therapy-approved-in-the-us/
Teva launches digital asthma and COPD rescue inhaler in USTeva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to Share XTeva launches digital asthma and COPD rescue inhaler in UShttps://pharmaphorum.com/news/fda-approves-tevas-digital-asthma-and-copd-rescue-inhaler/
Verona says FDA backs plan to take COPD drug into phase 3More than two years after first saying it would take its lead drug into a pivotal trial, Verona Share XVerona says FDA backs plan to take COPD drug into phase 3https://pharmaphorum.com/news/verona-says-fda-backs-plan-to-take-copd-drug-into-phase-3/
FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKThe FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by Share XFDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKhttps://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/
COPD: the world’s biggest neglected disease?We speak to Verona Pharma’s CEO Jan-Anders Karlsson to find out how the company is looking to tackle Share XCOPD: the world’s biggest neglected disease?https://pharmaphorum.com/r-d/views-analysis-r-d/copd-the-worlds-biggest-neglected-disease/
AZ sees triple approval in Japan for cancer and COPD drugsAstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its Share XAZ sees triple approval in Japan for cancer and COPD drugshttps://pharmaphorum.com/news/az-sees-triple-approval-in-japan-lynparza/
Novartis builds case for asthma drugs to challenge GSKNovartis has positive data for a two-drug asthma regimen that forms the backbone of its efforts to take Share XNovartis builds case for asthma drugs to challenge GSKhttps://pharmaphorum.com/news/novartis-asthma-drugs-challenge-gsk/
Boehringer looks to enhance COPD care with new registryBoehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience Share XBoehringer looks to enhance COPD care with new registryhttps://pharmaphorum.com/news/boehringer-enhance-copd-care-new-registry/
